• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Codexis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/11/25 4:01:18 PM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    8-K
    false 0001200375 0001200375 2025-06-10 2025-06-10
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 10, 2025

     

     

    Codexis, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-34705   71-0872999

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    200 Penobscot Drive

    Redwood City, CA 94063

    (Address of Principal Executive Offices) (Zip Code)

    (650) 421-8100

    Registrant’s telephone number, including area code

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading

    Symbols(s)

     

    Name of Each Exchange

    on Which Registered

    Common Stock, par value $0.0001 per share   CDXS   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Amendment to 2019 Incentive Award Plan

    As further described in Item 5.07 of this Current Report on Form 8-K, Codexis, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2025, at which the Company’s stockholders approved an amendment to the Company’s 2019 Incentive Award Plan, as amended (the “Amended 2019 Plan”) to add an additional 8,000,000 shares to the number of shares of Common Stock authorized for issuance under the Amended 2019 Plan. The Amended 2019 Plan had previously been approved, subject to stockholder approval, by the Board of Directors (the “Board”) on April 10, 2025.

    A more detailed summary of the material features of the Amended 2019 Plan are described in the section titled “Proposal 4 – Approval of an Amendment to Our 2019 Incentive Award Plan” in the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting, filed with the Securities and Exchange Commission on April 24, 2025 (the “Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2019 Plan, which is attached as Appendix A to the Proxy Statement.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    The following is a brief description of each matter voted upon at the Annual Meeting. A more complete description of each matter is set forth in the Proxy Statement. The vote results detailed below represent final results as certified by the Inspector of Elections.

    Proposal 1. Election of Directors.

    The Company’s stockholders elected David V. Smith and Dennis P. Wolf for a three-year term expiring at the 2028 annual meeting of stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal. The voting results are as follows:

     

         Number of Votes  
    Name of Nominee    For      Withheld      Broker Non-Votes  

    David V. Smith

         53,781,084        710,177        15,623,696  

    Dennis P. Wolf

         44,001,175        10,490,086        15,623,696  

    Proposal 2. Ratification of Independent Registered Public Accounting Firm.

    The Company’s stockholders ratified the selection by the Audit Committee of the Company’s board of directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results are as follows:

     

    Number of Votes

    For    Against    Abstain
    69,067,367    563,675    483,915

    Proposal 3. Non-binding, Advisory Vote on Executive Compensation.

    The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting results are as follows:

     

    Number of Votes

    For    Against    Abstain    Broker Non-Votes
    48,882,072    4,841,595    767,594    15,623,696


    Proposal 4. Approval of the Amendment to the Company’s 2019 Incentive Award Plan.

    The Company’s stockholders approved the Amended 2019 Plan. The voting results are as follows:

     

    Number of Votes

    For    Against    Abstain    Broker Non-Votes
    39,906,994    14,328,338    255,929    15,623,696


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CODEXIS, INC.
    Date: June 11, 2025     By:  

    /s/ Georgia Erbez

          Georgia Erbez
          Chief Financial Officer
    Get the next $CDXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Codexis downgraded by The Benchmark Company

    The Benchmark Company downgraded Codexis from Buy to Hold

    8/19/24 8:50:44 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Jefferies resumed coverage on Codexis with a new price target

    Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

    6/3/24 8:45:11 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Cantor Fitzgerald initiated coverage on Codexis with a new price target

    Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

    5/30/24 7:33:26 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    SEC Filings

    View All

    SEC Form S-8 filed by Codexis Inc.

    S-8 - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 5:15:35 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by Codexis Inc.

    10-Q - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 4:14:45 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CODEXIS, INC. (0001200375) (Filer)

    8/13/25 4:08:46 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $282,000 worth of shares (100,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/22/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $282,000 worth of shares (100,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/22/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Leadership Updates

    Live Leadership Updates

    View All

    Codexis Appoints Cynthia Collins to Board of Directors

    REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

    4/1/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

    REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact

    2/6/25 4:05:30 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Christos Richards to Board of Directors

    REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies

    1/16/25 4:05:27 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Financials

    Live finance-specific insights

    View All

    Codexis Reports Second Quarter 2025 Financial Results

    Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter marked a key strategic shift for Codexis," said Stephen Dilly, MBBS, PhD, Chairma

    8/13/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report Second Quarter 2025 Financial Results on August 13

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 2

    7/30/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

     Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

    5/22/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    9/26/24 9:27:32 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Codexis Inc.

    SC 13G/A - CODEXIS, INC. (0001200375) (Subject)

    9/18/24 4:50:02 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    7/12/24 4:15:13 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Codexis Reports Second Quarter 2025 Financial Results

    Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter marked a key strategic shift for Codexis," said Stephen Dilly, MBBS, PhD, Chairma

    8/13/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report Second Quarter 2025 Financial Results on August 13

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 2

    7/30/25 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

     Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon

    5/22/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials